期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

辛伐他汀两种剂量治疗冠心病血脂异常患者的疗效与安全性 被引量：4

下载PDF
导出
摘要 目的探讨辛伐他汀两种剂量治疗冠心病血脂异常患者的疗效与安全性。方法我院治疗的冠心病血脂异常患者90例,平均分为高剂量组和低剂量组各45例。高剂量组患者给予辛伐他汀20mg,低剂量组患者给予辛伐他汀10mg,口服治疗。结果用药90d和180d后,两组患者的TC和LDL-C检测结果与治疗前相比,均有明显的降低(P<0.05),而两组患者的HDL-C和TG,治疗后与治疗前相比,差异均不具有统计学意义(P>0.05)。但两组患者不同时期的TC和LDL-C检测结果相比,差异均无统计学意义(P>0.05)。高剂量组患者药物的降TC作用和降LDL-C作用明显优于低剂量组(P<0.05)。而药物的升HDL-C作用和降TG作用,两组患者相比,差异无统计学意义(P>0.05)。高剂量组患者降低TC和降低LDL-C的达标率明显高于低剂量组患者(P<0.05)。但在两个时段之间的达标率比较,差异均不具有统计学意义(P>0.05)。结论辛伐他汀用药剂量10mg及20mg均具有良好的调节冠心病血脂异常的作用,并且具有很好的安全性,同时20mg的作用效果更佳。
作者 常亮
机构地区 吉林省吉林市解放军第
出处 《中国医药指南》 2012年第22期209-210,共2页 Guide of China Medicine
关键词 冠心病 血脂异常 辛伐他汀 疗效 安全性
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献2

二级参考文献25

  • 1赵水平.急性冠状动脉综合征患者应尽早服用他汀类药物[J].中华心血管病杂志,2004,32(11):961-962. 被引量：81
  • 2张玉蓉,吕卓人.调脂治疗理念转变的思考[J].中华心血管病杂志,2006,34(8):760-761. 被引量：16
  • 3曾武涛,黄润莲,冷秀玉,刘东红,杨波,卢集森,陈科奇,陈国伟.辛伐他汀对冠心病患者血管内皮功能作用的量效关系[J].中国心血管杂志,2007,12(1):13-16. 被引量：8
  • 4Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J]. Lancet, 1992,340:1111-1115.
  • 5Deskttr-Smielecka E, Wykr-Towicz A, Kempa M, et al. The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolemia[J]. Coron Artery Di, 2001, 12: 143-148.
  • 6Santos AF, Keifel E, Bittar AE, et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study[J]. Transplant Proc,2001,33 : 1194-1195.
  • 7Kaeserneyer WH, Caldweil RB, Huang JZ, et al.Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions[J].J Am Coll Cardiol, 1999, 33:234-241.
  • 8Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors[J]. Circulation, 1998, 97:1129-1135.
  • 9Rosenson RS, Tangney CC. Antiatherothrombolic properties of statins: Implications for cardiovascular event reduction[J]. JAMA, 1998, 279:1643-1650.
  • 10Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis [J]. Lancet, 1992,340:1111.

共引文献18

同被引文献29

  • 1Chen ZM, Jiang LX,Chen YP, et al. Addition of clopidogrel toaspirin in 45,852 patients with acute myocardial infarction;randomized placebo-controlled trial〔J〕. Lancet, 2005, 366:1607-1621.
  • 2Payne CD, Li YG, Small DS,ei al. Increased active metabolitefor mat ion explains the greater platelet inhibition with prasug-rel com-pared to high-dose clopidogrel〔J〕. J Cardiovasc Phar-maco)2007.50: 555-562.
  • 3Gurbel PA’Bliden KP,Butler K,etal. Randomized doubleblindassessment of the ONSET and OFFSET of the antiplateleteffects of ticagrelor versus clopidogrel in patients with stablecoronary artery disease: the ONSET/OFFSET studyCJD. Circu-lation, 2009 ,120(25): 2577-2585.
  • 4Wallentin L. Becker R C,Budaj Ayet al. Ticagrelor versus clo-pidogrel in patients with actue coronary syndromes [J]. N EnglJ Med,2009,361(11) :1045-1057.
  • 5Biondi-zoccai G. Lotrionte M,Gaita Ffet al. Adjusted indirectcomparison meta-analysis of prasugrel versus ticagrelor for pa-tients with acute coronary syndromes CJ^l. Int J Cnrdiol, 2011,150(3):325-331.
  • 6Ramaraj R, Movahed ME, Hashemzadeh M Novel antiplateletagent ticagrelor in the management of acute coronary syndrome[J]_ J Irzterv Carddol, 2011,24(3) :199-207.
  • 7Connolly SJE, Michael D, Yusuf SE, et al. Dabigatran versusWarfarin in Patients with Atrial Fibrillation CJD. New EnglandJournal of Medicine,2009,361(12) : 1139-1151.
  • 8Athyros VG,TziomaIos K,Gossios TDfet al. Safety and effica-cy of long-term statin treatment for cardiovascular events in pa-tients with coronary heart disease and abnormal liver tests inthe Greek Atorvastatin and Coronary Heart EHsease Evaluation(GREACE)Study: A post-hoc analysisCJD. Lancet, 2010, 376(9756):1916-1922.
  • 9Musunuru K,Blumenthal RS. The implications of the ezetimi-be and simvastatin in hypercholesterolemia enhances athero-sclerosis regression trial: a return to first principles〔J〕. CHnCardiol 12008,31 (6) : 288-290.
  • 10Dudek D,Onuma Y.Ormiston JA^etal. Four-year clinical fol-low-up of the ABSORB everolimus-eluting bioresorbable vas-cular scaffold in patients with denovo coronary artery disease:the ABSORB trial〔J〕. Euro Intervention, 2011,7 (9): 1060-1061.

引证文献4

二级引证文献4

中国医药指南
2012年 第22期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部